Zhihu Group's net revenue for the fourth quarter was 2.58 billions RMB, estimated at 2.56 billions RMB.

Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer.

European MRO Network Upgrade Plan: GE Aerospace announces plans to invest approximately 40 million euros in maintenance, repair, and overhaul (MRO) and component repair facilities in Europe by 2026.

Financing Plan Details: Australian biotechnology company Kazia Therapeutics Limited (NASDAQ: KZIA) recently filed an F-1 form with the U.S. Securities and Exchange Commission (SEC), planning to raise up to 200 millions USD through the issuance of American Depositary Shares (ADS).

Financial Data Highlights: Ovid Therapeutics Inc. (NASDAQ: OVID) reported in its latest financial statement that as of December 31, 2025, the company held a total of $90.4 million in cash, cash equivalents, and marketable securities.